{"entity":{"id":"nct05163041","kind":"trial","name":"Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression","aka":[],"tldr":"A phase 1/2 trial of Nivolumab in advanced solid tumours, run by BicycleTx Limited, active and no longer recruiting.","summary":"Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression is a phase 1/2 interventional study registered as NCT05163041 by BicycleTx Limited, with 200 participants enrolled, started 2021-11-02 and due to reach its primary completion in 2026-08. Interventions recorded: BT7480 and Nivolumab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05163041","url":"https://clinicaltrials.gov/study/NCT05163041"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05163041","phase":"1/2","setting":"Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies","sponsor":"BicycleTx Limited","enrolled":200,"outcomes":[]},"route":"/trials/nct05163041/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}]}}